Iovance hammered as cell therapy disappoints
Lower – and shorter – efficacy add to serious doubts about the TIL therapy's future.
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
SITC 2021 – Incyte unveils its oral checkpoint blocker
There are some remissions, but peripheral neuropathy casts a long shadow.
Agenus investors wake up to inevitability
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
